VEGFA and atherosclerosis: Fundamental studies have also showed that hs-CRP could inhibit vascular endothelial growth factor-stimulated angiogenesis and indirectly promote vasoconstriction, thrombosis, and atherosclerosis [59, 60], increasing the risk of death from CVD [61].